BofA raised the firm’s price target on Mineralys Therapeutics (MLYS) to $43 from $38 and keeps a Buy rating on the shares. The firm made “modest” estimate adjustments after updating for Q2 results and guidance for a cash runway into 2027, the analyst tells investors in a post-Q2 SMid-Cap Biotech update note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 8/14/2025, According to Top Analysts
- Positive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position
- Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond
- Mineralys Therapeutics Reports Positive Q2 2025 Results
- Mineralys Therapeutics, Inc. (MLYS) Q2 Earnings Cheat Sheet